Glykoprotein-IIb/IIIaAntagonisten

H. Darius; T. Grosser

doi:10.1055/s-0038-1655350

Hämostaseologie, Inhaltsverzeichnis

Hamostaseologie 1998; 18(04): 171-179
DOI: 10.1055/s-0038-1655350

Übersichtsarbeiten/Review Articles

Schattauer GmbH

Glykoprotein-IIb/IIIaAntagonisten

H. Darius

¹II. Medizinische Klinik und Poliklinik (Direktor: Professor Dr. J. Meyer), Johannes-Gutenberg-Universität, Mainz

,

T. Grosser

¹II. Medizinische Klinik und Poliklinik (Direktor: Professor Dr. J. Meyer), Johannes-Gutenberg-Universität, Mainz

› Institutsangaben

Abstract

Zusammenfassung

Durch die funktionelle und molekulare Charakterisierung des thrombozytären Fibrinogenrezeptors (Glykoprotein-IIb/IIIa-Rezeptor; Integrin á_IIbâ₃) konnte die Bedeutung der Fibrinogenbindung für die Thrombozytenaggregation erkannt werden. Dies ist klinisch vor allem beim akuten Koronarsyndrom von Bedeutung. Als erster therapeutisch einsetzbarer Antagonist stand ein blockierendes Fragment eines monoklonalen Antikörpers zur Verfügung (Abciximab), das in verschiedenen Studien mit großem Erfolg bei Koronarinterventionen und bei instabiler Angina pectoris eingesetzt wurde. Durch Therapie der Patienten mit Abciximab konnte die Inzidenz der unerwünschten kardialen Ereignisse hochsignifikant reduziert werden. Synthetische Antagonisten für die intravenöse Anwendung sind ebenfalls mit Erfolg bei instabiler Angina und Koronarinterventionen angewandt worden, und die ersten Verbindungen sind bereits für die Therapie verfügbar. Die initial deutlich erhöhte Blutungsrate der Patienten unter Therapie mit G PI Ib/I I laAntagonisten konnte durch Reduktion der gleichzeitig applizierten Heparindosen deutlich vermindert werden. Andere Indikationen, wie die Behandlung des akuten Myokardinfarktes während einer Rekanalisationstherapie, werden zur Zeit eingehend untersucht. Ebenfalls Gegenstand intensiver klinischer Studien sind die oral resorbierbaren GPIIb/IIIa-Rezeptorantagonisten, die zur Nachbehandlung nach Koronarinterventionen oder akutem Koronarsyndrom entwickelt werden.

Schlüsselwörter

Glykoprotein-IIb/IIIa-Rezeptor - Fibrinogen-Rezeptor - Thrombozyten - akutes Koronarsyndrom

Volltext

Referenzen

LITERATUR
1 Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308: 159-68.
2 Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the confirmation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985; 76: 101-8.
3 Deckelbaum LI, Sax FL, Grossman W. Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein IIb/IIIa receptor. In: Sasahara AA, Loscalzo J. New therapeutic agents in thrombosis and thrombolysis. Marcel Dekker: 1997
4 Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W, Holt R, Jordan R, Berger H, Collen D, Coller BS. Pharmacodynamic study of F(ab’)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 86: 651-9.
5 Haas TA, Plow EF. The cytoplasmatic domaine of a_IIbß₃ . J Biol Chem 1996; 271: 947-50.
6 Jennings LK, Phillips DR. Purification of glycoproteins IIb and III from human platelet membranes and characterization of a calcium-dependent glycoprotein IIb-III complex. J Biol Chem 1982; 257: 10458-66.
7 Knight DM, Wagner C, Jordan R, McAleer MF, DeRita R, Fass DN, Coller BS, Weismann HF, Ghrayeb J. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol 1995; 32: 1271-81.
8 Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-9.
9 Markland JFS. Snake venoms. Drugs 1997; 54 (Suppl. 03) 1-10.
10 Müller Th. H., Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J. Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in men Circulation 1997; 96: 1130-8.
11 Niewiarowski S, McLane MA, Kloczewiak M. Disintegrins and other natural occuring antagonists of platelet fibrinogen receptors. Semin Haematol 1994; 31: 289-300.
12 Niiya K, Hodson E, Bader R, Byers-Ward V, Koziol JA, Plow EF, Ruggeri ZM. Increased surface expression of the membrane GPIIb/IIIa compex induced by platelet activation. Relationship to the binding of fibrinogen and platelet activation. Blood 1987; 70: 475-9.
13 Nurden AT. Polymorphisms of human platelet membrane glycoproteins: Structure and clinical significance. Thromb Haemostas 1995; 74: 345-51.
14 Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Eckmyn H, Vermylen J, Arnout J. MK-383 (L-700,4629 a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993; 88: 1512-7.
15 Phillips DR, Charo IF, Parise LV, Fitzgerald GA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988; 71: 831-43.
16 Poncz M, Eisman R, Heidenreich R, Silver SM, Vilaire G, Surrey S, Schwartz E, Bennett JS. Structure of platelet membrane glycoprotein IIb. Homology to the alpha subunit of the vitronectin and fibronectin membrane receptors. J Biol Chem 1987; 262: 8476-82.
17 Rabhi-Sabile S, Pidard D. Exposure of human platelets to plasmin results in the expression of irreversibly active fibrinogen receptors. Thromb Haemost 1995; 73: 693-8.
18 Schrör K. Antiplatelet drugs. A comparative review. Drugs 1995; 50: 7-28.
19 Schulman SP, Goldschmitt-Clermont PJ, Topol E. et al. Effects of Integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 1996; 94: 2083-9.
20 Seidl C, Siehl J, Kirchmaier CM, Seifried E. Analysis of glycoprotein Ia, Ib, IIa and IV RNA in platelets: Quantitative determination using fluorescence-based polymerase chain reaction. Haemostasis 1997; 27: 131-9.
21 Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757-64.
22 The Capture Investigators. Randomised Plazebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTUREstudy. Lancet 1997; 349: 1429-35.
23 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. N Engl J Med 1994; 330: 956-61.
24 The Epilog Investigators. Effect of the platelet glycoprotein IIb/IIIa receptor inhibitor abciximab with lower heparin dosages in ischemic complications of percutaneous coronary revascularisation. N Engl J Med 1997; 336: 1689-96.
25 The IMPACT-II Investigators. Effects of Competitive Platelet Glycoprotein IIb/IIIa Inhibition with Velofibatide (Integrilin) in Reducing Complications of Percutaneous Coronary Intervention: Results of the Randomized Clinical Trial IMPACT-II. Lancet 1997; 349: 1422-8.
26 The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505.
27 The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISMPLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
28 The Pursuit Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.
29 The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-53.
30 Topol EJ, Califf RM, Weismann HF, Ellis SG, Tchen JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M. et al. Randomised trial of coronary intervention with antibody against IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994; 343: 881-6.
31 Tschoepe D. The activated megacaryocyteplatelet-system in vascular disease: focus in diabetes. Sem Thromb Haemost 1995; 21: 152-60.
32 van Willigen G, Hers I, Gorter G, Akkerman JWN. Exposure of the ligand-binding sites on platelet integrin á_IIbâ₃ by phosphorylation of the â₃ subunit. Biochem J 1996; 314: 768-9.
33 Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 Binding to human platelets. Blood 1996; 88: 907-14.
34 Weisel JW, Nagaswami C, Vilaire G, Bennett JS. Examination of the platelet membrane glycoprotein IIb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy. J Biol Chem 1992; 267: 16637-43.
35 Wencel-Drake JD, Boudignon-Proudhon C, Dieter MG, Criss AB, Parise LV. Internalization of bound fibrinogen modulates platelet aggregation. Blood 1996; 87: 602-12.